NBY NovaBay Pharmaceuticals Inc.: רווח נקי למניה בארבעת הרבעונים האחרונים

The 12-month annual growth in earnings per share demonstrates the development dynamics of NovaBay Pharmaceuticals (NBY), where 96.70 characterizes this valuation parameter. The issuer is betting on Avenova brand recognition and the expansion of DTC sales. The absence of geopolitical threats in the US stabilizes the business, while final revenues are based on demand for eyelid hygiene products and the operational efficiency of ophthalmology networks.
NovaBay Pharmaceuticals - פילוחים אנליטיים ומדדי מפתח (NBY)

Earnings per share dynamics determine the fundamental value of NovaBay Pharmaceuticals (NBY), serving as an indicator of business scaling efficiency. By analyzing the YoY EPS change on a rolling 12-month basis, an investor tracks net income growth rates relative to the previous year, which is currently critical for assessing the success of the strategy to reduce reliance on a single brand through the launch of new product lines.